Medical release archive

European Respiratory Journal publishes Phase III TELOS trial for PT009 dual combination therapy in moderate to very severe chronic obstructive pulmonary disease

New data from real world evidence indicates need for better secondary prevention to reduce long-term ischaemic risk in heart attack survivors

AstraZeneca expands heart failure research with new Phase III DELIVER trial of Forxiga in patients with and without type-2 diabetes

Farxiga in combination with Onglyza demonstrates similar glycaemic control with additional benefits vs. insulin glargine in patients with type-2 diabetes

AstraZeneca and MedImmune present Phase II data for MEDI0382 at ADA 2018 demonstrating significant improvements in glycaemic control and weight loss in patients with type-2 diabetes

AstraZeneca presents Imfinzi (durvalumab) plus tremelimumab combination data at AACR Annual Meeting

BRILINTA (ticagrelor) associated with a reduction in risk for cardiovascular events, versus clopidogrel, in heart attack survivors with moderate kidney disease

Brilinta meets primary endpoint in Phase III thrombolysis trial

AstraZeneca enrols first patient in new Brilinta (ticagrelor) stroke trial

Risk of repeat heart attack twice as likely from occlusions in arteries that did not cause initial event